CE: DETAIL
Clinical Spotlights on Ovarian Cancer
These Clinical Spotlight interviews, with accompanying eNewsflash and downloadable slides, discuss the topic of targeting angiogenesis in the treatment of ovarian cancer with a focus on the following data release:
#LBA1: Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study
The first interview is an expert analysis with Gini Fleming, MD, from the University of Chicago, Illinois in the United States, and Bradley Monk, MD, from the University of California Irvine, Orange, California, United States
The second interview is a supplemental perspective and discussion with Bradley Monk, MD, from the University of California Irvine, Orange, California, United States, and Michael Birrer, MD, PhD, from the Massachusetts General Hospital, Boston, Massachusetts in the United States.
Expires on:
Jun 30, 2011
City: , AL
Cost:
Contact Hours:
Link to Program: http://primeoncology.org/2010/chicago/cs/cs3_2/index.html
Specialty / Area of Interest:
Oncology, Women's Health & Ob/Gyn
Category:
Medical
Presenter / Author: Gini Fleming, MD, from the University of Chicago, Illinois in the United States,
Sponsor / Supporter / Grant Provider: Roche
Provider of Program: Prime Oncology
|
|